A5084544284- Renal Transplantation Outcomes and Treatments
- COVID-19 Clinical Research Studies
- Organ Transplantation Techniques and Outcomes
- COVID-19 Impact on Reproduction
- Organ and Tissue Transplantation Research
- HIV/AIDS drug development and treatment
- Polyomavirus and related diseases
- Diabetes Management and Research
- Hematopoietic Stem Cell Transplantation
- Diabetes Treatment and Management
- Potassium and Related Disorders
- Clinical Nutrition and Gastroenterology
- Long-Term Effects of COVID-19
- Immunodeficiency and Autoimmune Disorders
- Pneumocystis jirovecii pneumonia detection and treatment
- Pharmacological Effects and Toxicity Studies
- Liver Disease and Transplantation
- Colorectal and Anal Carcinomas
- Drug Transport and Resistance Mechanisms
- Surgical site infection prevention
- Renal Diseases and Glomerulopathies
- Colorectal Cancer Surgical Treatments
- Metabolism, Diabetes, and Cancer
- Metabolism and Genetic Disorders
- Hydrogen Storage and Materials
Mount Sinai Hospital
2017-2025
Yale University
2021
Icahn School of Medicine at Mount Sinai
2020
Mount Sinai Medical Center
2017
Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione
2013
Abstract Background Oral neomycin tablets have been the standard of care for gut decontamination to prevent surgical site infections (SSIs) in patients undergoing colorectal procedures. In August 2022, a shortage oral prompted need an alternative agent. Based on previously published data, intravenous tobramycin solution administered orally was selected at our institution. The objective compare rates SSIs between and Methods A single-center, retrospective cohort study conducted adult Mount...
Abstract The influence of patient characteristics and immunosuppression management on COVID‐19 outcomes in kidney transplant recipients (KTRs) remains uncertain. We performed a single‐center, retrospective review all adult KTRs admitted to the hospital with confirmed between 03/15/2020 05/15/2020. Patients were followed from date admission up 1 month following discharge or study conclusion (06/15/2020). Baseline characteristics, laboratory parameters, compared survivors patients who died...
Herein, we report that Shroom3 knockdown, via Fyn inhibition, induced albuminuria with foot process effacement (FPE) without focal segmental glomerulosclerosis (FSGS) or podocytopenia. Interestingly, knockdown mice had reduced podocyte volumes. Human minimal change disease (MCD), where inactivation was reported, also showed lower glomerular volumes than FSGS. We hypothesized volume prevented the progression to To test this hypothesis, utilized unilateral and 5/6th nephrectomy models in...
Abstract Background Concerns have been raised regarding proceeding with kidney transplantation using standard immunosuppression in COVID‐19 endemic areas. Methods We performed a single‐center review of all adult transplants during the pandemic New York City. Patients were managed protocols, including lymphocyte depleting induction and trough‐guided tacrolimus. Retrospective data collected for 3 months from date or until study conclusion (5/7/2020). The primary outcomes assessed included...
Abstract Introduction Kidney dysfunction is a known complication of intestinal transplantation; however, the rate development and risk factors for chronic kidney disease (CKD) remain poorly defined. Methods This was single‐center retrospective review isolated adult allograft recipients from 2011 to 2019. Patients who died or experienced graft loss within 1‐year had prior transplant were excluded. Estimated glomerular filtration (eGFR) calculated using CKD‐EPI equation at 0‐, 6‐ 12‐months...
Human leukocyte antigen allosensitization prior to transplant can increase the risk of early graft loss and prolong waitlist times for intestinal candidates. Desensitization offers a potential therapeutic option reduce quantity preformed antibodies organ allocation facilitate transplantation with more immunologically compatible donor allograft. However, there remains paucity data guide use desensitization in setting transplantation. As result, this review we evaluate existing literature...
Abstract Early conversion from a calcineurin inhibitor to belatacept has the potential improve long‐term renal allograft function; however, there remains limited experience with this strategy among African Americans and patients preformed donor‐specific antibodies (DSA). To examine these subgroups, we performed single‐center review of kidney transplant recipients converted within 1‐year between 01/2011 10/2017. All received lymphocyte‐depleting induction maintenance tacrolimus mycophenolate...
Abstract Background Trough‐adjusted tacrolimus is commonly prescribed following intestinal transplantation to prevent allograft rejection. Despite established practice, there remains limited direct evidence linking levels with improved clinical outcomes. Methods This was a single‐center review of all adult non‐liver containing recipients from 2011 2018. Patients received lymphocyte depleting induction and maintenance immunosuppression consisting corticosteroid taper. Tacrolimus...
The coronavirus disease 2019 (COVID-19) pandemic led to a precipitous drop in the number of kidney transplants performed 2020, due redistribution healthcare resources assist with managing surge critically ill patients, as well concern for increased infection-related mortality chronic immunosuppression.1, 2 While many transplant centers have subsequently resumed normal activities, 2021 brings it new challenge waitlist candidates prior COVID-19 infections, which will disproportionately impact...
Abstract There are only scattered case reports documenting belatacept use in HIV + kidney transplant recipients. We performed a retrospective review to describe short‐term outcomes following conversion cohort of patients. Patients were included if they converted between May 2015 and 2019, had an HIV‐ donor, received ≥4 doses belatacept. All patients treated with non‐depleting induction triple maintenance immunosuppression. Allograft HIV‐related collected from the date infusion until 2020....
Background: Higher rates of corrected QT (QTc) prolongation have been reported in patients with cirrhosis. The impact liver transplantation and prescription medications on the natural history QTc has yet to be well characterized. Methods: This was a single-center review receiving (group 1) or listed for 2) transplant during 2014. Patients group 1 were followed prospectively from date assess normalization posttransplant. In 2, evaluated listing up until December 2015 prevalence among...
Recommendations regarding the appropriateness of renal transplantation in patients with prior hematologic malignancies are limited. Given lack available data, studies needed to assess which these will maximally benefit from transplantation. This study was undertaken describe incidence new or recurrent malignancy as well patient and allograft survival, acute rejection, serious infections receiving a single center retrospective review all adult previous who received living deceased between...
Despite numerous recent advances in the management of patients with type 2 diabetes, there remains a paucity data to guide sequential treatment intensification.This was single-center, retrospective cohort study receiving metformin, basal insulin, and sulfonylurea who were started on third noninsulin agent or prandial insulin. The primary outcome for this change A1C at 6 months after intensification. Secondary outcomes included weight months, 1 year, percentage achieving an <7.5% documented...
Introduction: Insulin is commonly prescribed to manage early post-kidney transplant hyperglycemia due its flexibility. Studies comparing the effectiveness of oral therapies on glycemic outcomes remain limited. Project aims: The purpose this program evaluation was analyze our experience using antiglycemic agents immediately transplant, compared patients managed with insulin monotherapy. Design: This a single-center, retrospective review adult kidney recipients new or worsening between...
Background: Preformed donor specific antibody (DSA) is associated with a poor outcome after intestinal transplant (ITX): To describe preliminary results from stratified approach to managing anti-HLA prior ITX. Methods: Retrospective review of patients listed for ITX January 2010–2016. All had baseline solid-phase (Luminex) testing done detect For panel reactive (PRA) > 30%, desensitization was using (Figure 1). Patients PRA 30% were initially treated standard therapy consisting IVIG and...
Introduction: Tacrolimus (TAC) is a mainstay of immunosuppression after intestinal transplantation (ITX), but dosing complicated by narrow therapeutic index and broad variability. Studies in kidney liver have identified the influence CYP3A5 ABCB1 genetic variants, both which are expressed epithelium, on TAC pharmacokinetics; however, no studies examined pharmacogenetic (PGX) variation exposure ITX. Methods: This was single-center, retrospective analysis adult ITX recipients from 2011–2018....